PINTAUDI, BASILIO
 Distribuzione geografica
Continente #
EU - Europa 612
NA - Nord America 512
AS - Asia 122
SA - Sud America 4
Continente sconosciuto - Info sul continente non disponibili 1
Totale 1.251
Nazione #
US - Stati Uniti d'America 511
IE - Irlanda 169
IT - Italia 145
SE - Svezia 132
CN - Cina 108
PL - Polonia 64
FR - Francia 33
DE - Germania 20
FI - Finlandia 15
GB - Regno Unito 14
UA - Ucraina 8
BE - Belgio 6
IN - India 6
VN - Vietnam 4
EC - Ecuador 3
NL - Olanda 2
RU - Federazione Russa 2
TR - Turchia 2
AL - Albania 1
CA - Canada 1
CL - Cile 1
EU - Europa 1
KR - Corea 1
PK - Pakistan 1
RO - Romania 1
Totale 1.251
Città #
Dublin 169
Chandler 110
Nyköping 79
Warsaw 64
Messina 63
Ashburn 59
Beijing 41
Jacksonville 34
Ann Arbor 23
Princeton 23
Cambridge 20
Medford 19
Catania 15
Wilmington 15
Dearborn 12
Des Moines 12
Nanjing 11
Jinan 10
Seattle 10
Bremen 9
Hebei 8
Boardman 7
Houston 7
Brussels 6
Haikou 6
San Mateo 6
Shenyang 5
Washington 5
Caltagirone 4
Dong Ket 4
Hangzhou 4
London 4
Southwark 4
Trecastagni 4
Woodbridge 4
Zhengzhou 4
Fuzhou 3
Guangzhou 3
Hyderabad 3
Nanchang 3
New York 3
Pune 3
Quito 3
Viagrande 3
Augusta 2
Bologna 2
Finale Emilia 2
Greifswald 2
Maranello 2
Mascalucia 2
Ningbo 2
Rome 2
Siracusa 2
Taizhou 2
Tianjin 2
Belpasso 1
Capoterra 1
Carini 1
Changsha 1
Chicago 1
Clearwater 1
Dumfries 1
Hefei 1
Lahore 1
Los Angeles 1
Milan 1
Munich 1
Norwalk 1
Nuremberg 1
Ottawa 1
Redwood City 1
Rio Saliceto 1
San Giuseppe Vesuviano 1
Seoul 1
Taiyuan 1
Villa San Giovanni 1
Vittoria 1
Winston-Salem 1
Totale 949
Nome #
Myo-inositol Supplementation for Prevention of Gestational Diabetes in Obese Pregnant Women: A Randomized Controlled Trial 102
Effects of myo-inositol on glucose variability in women with gestational diabetes 84
Wnt antagonist sclerostin and Dickkopf-1 in gestational diabetes 80
The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes. 76
Effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome: a perspective, randomized, placebo-controlled study. 74
Myo-inositol may prevent gestational diabetes onset in overweight women: a randomized, controlled trial 74
Perinatal outcome in a Caucasian population with gestational diabetes and preexisting diabetes first diagnosed in pregnancy 73
Depressione, ansia e rabbia in soggetti affetti da diabete mellito di tipo 1 [Depression, anxiety and anger in patients with type 1 diabetes mellitus] 64
Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial 64
SCLEROSTIN AND DICKKOPF-1 LEVELS IN PREGNANT WOMEN WITH GESTATIONAL DIABETES 57
Serum thyroid hormone autoantibodies in type 1 diabetes mellitus 55
Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs 55
Diagnosis of gestational diabetes mellitus: italian perspectives on risk factor based screening 55
"Normoalbuminuric" diabetic nephropathy: tubular damage and NGAL. 52
Phalangeal quantitative ultrasound and metabolic control in premenopausal women with type 1 diabetes mellitus 49
The complex interplay between clinical and person-centered diabetes outcomes in the two genders 47
Cardiac diastolic evaluation in pregnant women with abnormal glucose tolerance: an opportunity to detect the early and subclinical alterations and prevent cardiovascular diseases 45
SCLEROSTIN LEVELS IN TYPE 1 DIABETES MELLITUS: GENEDER DIFFERENCES AND ASSOCIATION WITH CLINICAL FEATURES 45
One-year effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome 43
CORRESPONDENCE BETWEEN FIRST TRIMESTER FASTING GLICEMIA AND ORAL GLUCOSE TOLERANCE TEST IN GESTATIONAL DIABETES DIAGNOSIS 43
The impact of clinical and psychological characteristics on alexithymia in type 1 diabetes 39
Improvement of selective screening strategy for gestational diabetes through a more accuratedefinition of high-risk groups 36
The efficacy of PCSK9 inhibitors on major cardiovascular events and lipid profile in patients with diabetes: a systematic review and meta-analysis of randomized controlled trials 9
Totale 1.321
Categoria #
all - tutte 4.559
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.559


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20193 0 0 0 0 0 0 0 0 0 0 1 2
2019/2020156 9 1 4 5 4 15 8 19 19 26 35 11
2020/2021240 20 16 50 11 24 9 16 14 33 31 10 6
2021/2022170 2 22 3 12 4 2 6 13 5 44 13 44
2022/2023472 34 58 21 18 42 40 3 16 214 1 21 4
2023/2024138 12 14 6 29 17 24 7 12 6 10 1 0
Totale 1.321